Ignite Creation Date:
2024-05-06 @ 8:25 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02732249
Status:
COMPLETED
Last Update Posted:
2018-06-26
First Post:
2016-04-04
Brief Title:
Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment
Sponsor:
Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
A Randomized Clinical Trial of ClarithromycinBismuth Containing Quadruple Therapy for Helicobacter Pylori First-line Treatment
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Standard triple therapy including a proton pump inhibitor PPI and clarithromycin with either amoxicillin or metronidazole are no longer recommended as empirical first-line therapy to treat Helicobacter pylori infection because of high antibiotic resistance It is unknown whether the addition of bismuth overcome antibiotic resistance This study is designed to evaluate the efficacy and safety of the addition of bismuth to standard triple therapy for H pylori first-line eradication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None